BR9710738A - Matriz para administrar medicamentos transdermalmente para co-administra-Æo de estradiol e outro esterÄide - Google Patents

Matriz para administrar medicamentos transdermalmente para co-administra-Æo de estradiol e outro esterÄide

Info

Publication number
BR9710738A
BR9710738A BR9710738A BR9710738A BR9710738A BR 9710738 A BR9710738 A BR 9710738A BR 9710738 A BR9710738 A BR 9710738A BR 9710738 A BR9710738 A BR 9710738A BR 9710738 A BR9710738 A BR 9710738A
Authority
BR
Brazil
Prior art keywords
estradiol
steroid
matrix
administration
administering drugs
Prior art date
Application number
BR9710738A
Other languages
English (en)
Inventor
Venkateshwaran Srinivasan
Charles D Ebert
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of BR9710738A publication Critical patent/BR9710738A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9710738A 1996-07-19 1997-07-02 Matriz para administrar medicamentos transdermalmente para co-administra-Æo de estradiol e outro esterÄide BR9710738A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/683,892 US5783208A (en) 1996-07-19 1996-07-19 Transdermal drug delivery matrix for coadministering estradiol and another steroid
PCT/US1997/011673 WO1998003137A1 (en) 1996-07-19 1997-07-02 Transdermal drug delivery matrix for coadministering estradiol and another steroid

Publications (1)

Publication Number Publication Date
BR9710738A true BR9710738A (pt) 1999-08-17

Family

ID=24745888

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710738A BR9710738A (pt) 1996-07-19 1997-07-02 Matriz para administrar medicamentos transdermalmente para co-administra-Æo de estradiol e outro esterÄide

Country Status (21)

Country Link
US (1) US5783208A (pt)
EP (1) EP0921774B1 (pt)
JP (2) JP4212115B2 (pt)
KR (1) KR100628796B1 (pt)
CN (2) CN100536835C (pt)
AT (1) ATE339172T1 (pt)
AU (1) AU714590B2 (pt)
BR (1) BR9710738A (pt)
CA (1) CA2259532C (pt)
DE (1) DE69736671T2 (pt)
DK (1) DK0921774T3 (pt)
ES (1) ES2271970T3 (pt)
HK (2) HK1020864A1 (pt)
HU (1) HUP9904369A3 (pt)
IL (1) IL127708A (pt)
NO (1) NO325232B1 (pt)
NZ (1) NZ333558A (pt)
PL (1) PL188009B1 (pt)
PT (1) PT921774E (pt)
WO (1) WO1998003137A1 (pt)
ZA (1) ZA976035B (pt)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
PL181582B1 (pl) * 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
DE19834007C1 (de) * 1998-07-29 2000-02-24 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung
BR9814415A (pt) * 1998-10-23 2000-10-10 Idea Innovat Dermale Appl Gmbh "método para desenvolver, testar e utilizar associados de macromoléculas e agregados de complexos para carga útil aumentada e velocidades de desassociação controláveis"
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
WO2000034461A2 (en) * 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions and methods of modulating cholesterol metabolism
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
EP1754488A1 (en) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
AU5409699A (en) * 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
CA2406064C (en) 2000-04-26 2011-03-15 Watson Pharmaceuticals, Inc. Minimizing adverse experience associated with oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
CN1541112A (zh) * 2001-08-10 2004-10-27 �ù���ҩ��ʽ���� 经皮吸收制剂
KR20030041596A (ko) * 2001-11-20 2003-05-27 삼일페인트공업 주식회사 의료용 팻치에 적용되는 아크릴 점착제의 제조방법
US7921999B1 (en) * 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
EP1811961A2 (en) * 2004-11-12 2007-08-01 Idea Ag Extended surface aggregates in the treatment of skin conditions
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
US20090169602A1 (en) * 2005-11-23 2009-07-02 Universität Zürich Allergy Treatment by Epicutaneous Allergen Administration
CN101370453B (zh) * 2005-12-14 2013-12-18 努沃研究公司 用于皮肤输送药物的组合物和方法
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
DK2623605T3 (en) 2007-04-09 2019-03-25 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
CA2840407A1 (en) * 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
CA2976814C (en) 2007-08-27 2022-12-13 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods for treating influenza
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2535428B1 (en) 2007-10-01 2015-09-09 Longhorn Vaccines and Diagnostics, LLC Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
CA2796399C (en) 2010-04-23 2021-08-24 Shannon Elizabeth Boye Raav-guanylate cyclase compositions and methods for treating leber congenital amaurosis-1 (lca1)
EP3567106A1 (en) 2010-04-23 2019-11-13 University of Massachusetts Cns targeting aav vectors and methods of use thereof
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
KR20140145947A (ko) 2011-03-16 2014-12-24 암젠 인크 Nav1.3과 nav1.7의 유효한 선별적 저해제
ES2661680T3 (es) 2011-04-21 2018-04-03 University Of Massachusetts Composiciones basadas en VAAr y métodos para tratar deficiencias de alfa-1 anti-tripsina
US10149834B2 (en) 2011-12-01 2018-12-11 Teikoku Seiyaku Co., Ltd. Ropinirole-containing adhesive patch
JP6104173B2 (ja) 2011-12-01 2017-03-29 帝國製薬株式会社 ロピニロール含有貼付剤
EP2806890A4 (en) 2012-01-26 2015-09-02 Longhorn Vaccines & Diagnostics Llc COMPOSITE ANTIGENIC SEQUENCES AND VACCINES
UY35397A (es) 2013-03-12 2014-10-31 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
AU2015231294B2 (en) 2014-03-18 2020-10-29 University Of Massachusetts rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
EP3134522B1 (en) 2014-04-25 2021-10-06 University of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
JP6842410B2 (ja) 2014-10-03 2021-03-17 ユニバーシティ オブ マサチューセッツ 新規の高効率ライブラリーにより同定されるａａｖベクター
BR112017007737A2 (pt) 2014-10-21 2018-01-30 Univ Massachusetts variantes de aav recombinantes e usos das mesmas
WO2016100575A1 (en) 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
CA3007301A1 (en) 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
CN115287301A (zh) 2016-03-03 2022-11-04 马萨诸塞大学 用于非病毒基因转移的末端封闭型线性双链体dna
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
CN110506119A (zh) 2016-10-13 2019-11-26 马萨诸塞大学 Aav衣壳设计
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
US20210023241A1 (en) 2018-03-23 2021-01-28 University Of Massachusetts Gene therapeutics for treating bone disorders
WO2019210269A1 (en) 2018-04-27 2019-10-31 University Of Massachusetts Aav capsids identified by in vivo library selection
US20220033824A1 (en) 2018-11-29 2022-02-03 University Of Massachusetts Modulation of sptlc1 via recombinant adeno-associated vectors
EP3927380A1 (en) 2019-02-22 2021-12-29 University of Massachusetts Oxr1 gene therapy
CA3150330A1 (en) 2019-09-13 2021-03-18 Peter D. YURCHENCO LAMININ-LINKER POLYMERIZATION PROTEINS COMPATIBLE WITH AAV
AU2021225035A1 (en) 2020-02-21 2022-10-13 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
BR112022019304A2 (pt) 2020-03-31 2022-12-06 Univ Massachusetts Variantes de capsídeo de aav e usos das mesmas
CA3178726A1 (en) 2020-05-21 2021-11-25 Gregory LIZEE T cell receptors with vgll1 specificity and uses thereof
EP4196494A1 (en) 2020-08-17 2023-06-21 Massachusetts Institute of Technology Shank3 gene therapy approaches
EP4255457A1 (en) 2020-12-03 2023-10-11 University of Massachusetts Development of novel gene therapeutics for fibrodysplasia ossificans progressiva
KR20240017813A (ko) 2021-05-10 2024-02-08 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 신경질환 치료용 약학적 조성물
MX2024003778A (es) 2021-09-30 2024-04-10 Akouos Inc Composiciones y metodos para el tratamiento de la perdida de audicion asociada a kcnq4.
WO2023164545A1 (en) 2022-02-23 2023-08-31 Massachusetts Institute Of Technology Methods for upregulating shank3 expression

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954487A (en) * 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
IL61721A (en) * 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
JPS60123417A (ja) * 1983-12-07 1985-07-02 Nitto Electric Ind Co Ltd 薬物投与部材
JPS6160620A (ja) * 1984-09-03 1986-03-28 Teijin Ltd ピログルタミン酸エステル類を含有する医薬品組成物
US5296230A (en) * 1985-02-25 1994-03-22 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4762851A (en) * 1985-11-29 1988-08-09 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
GB8811408D0 (en) * 1988-05-13 1988-06-15 Unilever Plc Cosmetic composition
US5200190A (en) * 1988-10-11 1993-04-06 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneous pharmaceutical preparation
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
JPH04342532A (ja) * 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収貼付剤
JP3086288B2 (ja) * 1991-07-23 2000-09-11 扶桑薬品工業株式会社 経皮吸収製剤
JP2948423B2 (ja) * 1992-08-19 1999-09-13 富士写真フイルム株式会社 カリウムイオン分析用イオン選択電極
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
WO1995017896A1 (fr) * 1993-12-27 1995-07-06 Akzo Nobel N.V. Preparation pour absorption par voie percutanee
FR2717688B1 (fr) * 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
JPH0827003A (ja) * 1994-07-22 1996-01-30 Sekisui Chem Co Ltd 経皮吸収製剤
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme

Also Published As

Publication number Publication date
PL331239A1 (en) 1999-07-05
AU3650397A (en) 1998-02-10
CA2259532C (en) 2008-10-07
HK1020864A1 (en) 2000-05-26
KR100628796B1 (ko) 2006-09-27
HUP9904369A3 (en) 2000-11-28
CN1225568A (zh) 1999-08-11
ZA976035B (en) 1998-06-24
HK1078470A1 (en) 2006-03-17
NO325232B1 (no) 2008-03-03
US5783208A (en) 1998-07-21
IL127708A0 (en) 1999-10-28
JP4212115B2 (ja) 2009-01-21
NZ333558A (en) 2000-05-26
ES2271970T3 (es) 2007-04-16
NO990179D0 (no) 1999-01-15
EP0921774A1 (en) 1999-06-16
CN100536835C (zh) 2009-09-09
IL127708A (en) 2004-02-19
DK0921774T3 (da) 2007-01-29
HUP9904369A2 (hu) 2000-04-28
JP2006342186A (ja) 2006-12-21
CN1204859C (zh) 2005-06-08
CN1636555A (zh) 2005-07-13
PT921774E (pt) 2006-12-29
PL188009B1 (pl) 2004-11-30
KR20000067934A (ko) 2000-11-25
DE69736671T2 (de) 2007-09-13
JP2000514695A (ja) 2000-11-07
DE69736671D1 (de) 2006-10-26
CA2259532A1 (en) 1998-01-29
ATE339172T1 (de) 2006-10-15
AU714590B2 (en) 2000-01-06
NO990179L (no) 1999-01-15
WO1998003137A1 (en) 1998-01-29
EP0921774B1 (en) 2006-09-13
EP0921774A4 (en) 1999-08-25

Similar Documents

Publication Publication Date Title
BR9710738A (pt) Matriz para administrar medicamentos transdermalmente para co-administra-Æo de estradiol e outro esterÄide
DK0732922T3 (da) Transdermal afgivelsesindretning
ES2147858T3 (es) Matriz para el suministro transdermico de farmacos.
NZ316026A (en) A transdermal therapeutic system (a hormone patch) in which drugs are contained which are released into the skin comprising a backing film and a pressure sensitive adhesive
NO962933L (no) Östradiol-penetrasjonsforsterker for transdermal administrering
MX9804871A (es) Dispositivo transdermico para suministro de flurbiprofeno.
ZA977832B (en) Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents.
HUP9802326A2 (hu) 17-Dezacetil-norgesztimát vagy valamely ösztrogénnel kombinált hatóanyag bevitelére alkalmas transzdermális készítmény
ES2196578T3 (es) Copolimero en bloque.
NO940313L (no) Transdermale, terapeutiske systemer
DK0662822T3 (da) Tofasematrix til et afgivelsessystem til vedvarende afgivelse af lægemidler
DE59410103D1 (de) Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil
NO307644B1 (no) Transdermalt, terapeutisk system med krystalliseringsinhibitor
ATE238778T1 (de) Transdermales therapeutisches system zur abgabe von hormonen
NO20000814L (no) Identifikasjon for klebende flateformede dermale og transdermale terapeutiske administrasjonsformer under anvendelse av et klebende plaster som informasjonsbærer, såvel som fremgangsmåte for deres fremstilling
HUP9904181A2 (hu) Felületstabilizált gyógyszerészeti készítmény bőrön való alkalmazáshoz
DE59910944D1 (de) Transdermales therapeutisches system zur anwendung von candesartan
TR200102915T2 (tr) Etkili bir nöroleptik ilaç ihtiva eden transdermal terapötik sistem.
NO991047L (no) Transdermal terapeutisk tilnµrming involverende en kombinasjon av aktive substanser inneholdende °striol

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25D Requested change of name of applicant approved
B25A Requested transfer of rights approved

Free format text: WATSON PHARMACEUTICALS, INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 37, INDEFIRO O PRESENTE PEDIDO, TENDO POR BASE O ARTIGO 8O COMBINADO COM O ARTIGO 13 DA LEI 9279 DE 14/05/96.

B12B Appeal against refusal [chapter 12.2 patent gazette]